EUCTR2007-004120-21-IT
Active, Not Recruiting
N/A
X01-315-02 / ?A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma? - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)
VICAL INCORPORATED0 sites375 target enrollmentNovember 10, 2008
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Recurrent metastatic melanoma
- Sponsor
- VICAL INCORPORATED
- Enrollment
- 375
- Status
- Active, Not Recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Able and willing to provide informed consent and sign the informed consent form \- Age 18 or more years \- ECOG performance status of 0 or 1 \- Histologically confirmed recurrent metastatic melanoma, which may have received primary surgical resection, adjuvant therapy, and/or biotherapy \- At least one injectable lesion (cutaneous, subcutaneous, or nodal lesion) \&\#8805;1 cm2 and \&\#8804;25 cm2\. Lesions between 25 cm2 and 100 cm2 are not injected but may be followed as target lesions \- LDH within normal limits \- Serum creatinine \&\#8804; 2\.0 mg/dL \- Platelet count 100,000/mm3 or more \- White blood cell count 2500/mm3 or more \- Male and female subjects of child bearing potential must agree to use an effective method of contraception \- Negative pregnancy test for women of child bearing potential
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •\- Prior cytotoxic chemotherapy for malignant melanoma \- Prior Allovectin\-7R injection(s) \- Any lesion 100 cm2 or more \- History of visceral metastasis, M1c, other than lung (M1b not excluded) \- Surgery as a curative option \- Radiation therapy, immunosuppressive therapy or biologic therapy within four weeks prior to trial entry \- Major surgery within two weeks prior to trial entry \- Known positive HIV serology \- Other malignancy not currently in remission or unlikely to have been cured with prior therapy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or low grade prostate cancer) \- Concurrent immunosuppressive therapy, anticancer therapy or investigational treatment \- Active autoimmune disease requiring immunosuppressive or other therapies; e.g. Hashimoto?s Disease, Systemic Lupus Erythematosus, autoimmune hepatitis, Wegner?s granulomatosis, etc. \- Significant psychiatric disorders that would make compliance with the protocol difficult or would compromise ability to give informed consent \- Female subjects who are pregnant or lactating
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEX GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients with Unresectable Stage IIIb, IIIc and IV Diseasenresectable Stage IIIb, IIIc and IV MelanomaEUCTR2008-006140-20-GBBioVex Inc437
Active, Not Recruiting
N/A
A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylurea in Combination With MetformiDiabetes Mellitus type 2MedDRA version: 12.1Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2010-018318-62-HUMerck & Co., Inc.424
Completed
Phase 3
A Phase III Randomized Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylurea in Combination With MetformiCTRI/2010/091/000528Merck Co Inc424
Active, Not Recruiting
Phase 1
A phase III clinical trial to evaluate patient´s preference of subcutaneous trastuzumab (SC) versus intravenous (IV) administration in patients with HER2 positive Advanced Breast Cancer (ABC) who have received intravenous trastuzumab at least 4 months and without disease progressioPatients with HER2 positive Advanced Breast Cancer receiving trastuzumab with or without CT or HT therapy for at least four months without evidence of disease progression and a life expectancy of at least 3 months.MedDRA version: 14.1 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-004928-38-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)15
Active, Not Recruiting
N/A
HPV vaccine for the treatment and prevention of recurrent laryngeal papillomatosis, which is a bening tumor in the upper airways caused by HPVRecurrant respiratory papillomatosisTherapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]EUCTR2013-003049-41-HUational Institute of Child Health